Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Shareholders held by Cocrystal Pharma, Inc. on June 29, 2015. The filing details the voting results for six proposals submitted to security holders, including the election of directors, approval of an equity incentive plan, and a reverse stock split.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes rather than financial performance data.
Material Changes and Voting Results
Shareholders approved all six proposals presented at the meeting with significant majorities:
- Election of Directors: All seven nominees were elected with over 99% of votes cast.
- 2015 Equity Incentive Plan: Approved and ratified by over 99% of votes cast.
- Reverse Stock Split: Shareholders approved a 1-for-5 split ratio (511,571,910 votes for) over the 1-for-8 and intermediate options.
- Executive Compensation (Say-on-Pay): Approved by over 99% of votes cast.
- Frequency of Say-on-Pay Vote: Shareholders voted overwhelmingly (over 98%) for a three-year frequency.
- Independent Auditor: BDO USA, LLP was ratified as the independent registered public accounting firm for fiscal year 2015 by over 99% of votes cast.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results pursuant to Item 5.07.
Key Facts for Investor Verification
- Confirmation of the effective date and implementation details of the approved 1-for-5 reverse stock split.
- Verification of the total number of shares outstanding post-split.
- Review of the definitive proxy statement filed on June 1, 2015, for detailed terms of the 2015 Equity Incentive Plan.
- Confirmation of the new board composition following the election of the seven directors.